Richard Chen Sells 3,998 Shares of Personalis (NASDAQ:PSNL) Stock

Personalis, Inc. (NASDAQ:PSNL) CMO Richard Chen sold 3,998 shares of the stock in a transaction that occurred on Friday, September 18th. The stock was sold at an average price of $16.22, for a total value of $64,847.56. Following the completion of the transaction, the chief marketing officer directly owned 169,882 shares in the company, valued at approximately $2,755,486.04. This trade represents a 2.30% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Personalis Stock Performance

NASDAQ PSNL traded up $0.12 on Tuesday, reaching $16.36. 1,369,078 shares of the stock traded hands, compared to its average volume of 2,690,633. Personalis, Inc. has a 12 month low of $4.95 and a 12 month high of $18.89. The company has a market cap of $1.71 billion, a price-to-earnings ratio of -15.01 and a beta of 2.31. The company has a fifty day moving average price of $15.06 and a 200-day moving average price of $10.89.

Personalis (NASDAQ:PSNL) last posted its quarterly earnings results on Tuesday, August 4th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.04). The firm had revenue of $22.36 million for the quarter, compared to the consensus estimate of $16.69 million. Personalis had a negative return on equity of 46.47% and a negative net margin of 153.84%. As a group, research analysts anticipate that Personalis, Inc. will post -1.07 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Personalis

Institutional investors and hedge funds have recently bought and sold shares of the company. Merck & Co. Inc. acquired a new position in shares of Personalis during the second quarter worth $188,202,236. BlackRock Inc. acquired a new stake in shares of Personalis in the 2nd quarter worth $94,905,000. Bank of America Corp DE acquired a new stake in shares of Personalis in the 2nd quarter worth $24,395,000. AIGH Capital Management LLC purchased a new position in Personalis during the 2nd quarter worth $22,981,000. Finally, Dimensional Fund Advisors LP grew its stake in Personalis by 8.4% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,066,248 shares of the company’s stock worth $6,791,000 after buying an additional 83,074 shares during the last quarter. 61.91% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have commented on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Personalis in a research report on Friday, July 17th. Needham & Company LLC downgraded shares of Personalis from a “buy” rating to a “hold” rating in a research note on Monday, July 20th. Craig Hallum lowered shares of Personalis from a “buy” rating to a “hold” rating and set a $16.25 price objective on the stock. in a report on Monday, August 24th. Wall Street Zen downgraded shares of Personalis from a “hold” rating to a “sell” rating in a research note on Saturday, June 13th. Finally, Morgan Stanley upped their target price on Personalis from $9.00 to $13.00 and gave the stock an “equal weight” rating in a report on Thursday, July 9th. Four equities research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Personalis currently has an average rating of “Hold” and an average price target of $14.54.

Personalis Company Profile

Personalis, Inc is a genomics company focused on precision oncology and advanced molecular testing. The company develops and commercializes genomic products designed to help identify, monitor and characterize cancer, supporting more informed treatment decisions and the development of targeted therapies.

Its offerings include tissue- and blood-based tumor profiling, liquid biopsy testing and immune profiling. Personalis’ technologies are designed to detect and track tumor-derived signals, evaluate genomic alterations and provide insights into the interaction between cancer and the immune system.